Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04149574 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT04149574 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 13 participants.
The verdict
NCT04149574, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
Interventions
- OTHER Placebo
- DRUG nivolumab
- BIOLOGICAL Bacillus Calmette-Guérin (BCG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04149574
The ClinicalTrials.gov registry entry for NCT04149574 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04149574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04149574 about?
NCT04149574 is a clinical study titled "A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)". A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
What is the current status of trial NCT04149574?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2020-01-15. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04149574?
The interventions under investigation include: Placebo (OTHER), nivolumab (DRUG), Bacillus Calmette-Guérin (BCG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04149574?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.